Epstein-Barr virus: the mastermind of immune chaos

被引：26

作者：

Silva, Jean de Melo ^{[1
,2
]}

Alves, Carlos Eduardo de Castro ^{[1
]}

Pontes, Gemilson Soares ^{[1
,2
]}

机构：

[1] Natl Inst Amazonian Res INPA, Lab Virol & Immunol, Manaus, AM, Brazil

[2] Univ Fed Amazonas, Inst Biol Sci, Postgrad Program Basic & Appl Immunol, Manaus, AM, Brazil

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷

关键词：

EBV; herpesvirus; evasion; innate immunity; acquired immunity; NF-KAPPA-B; NATURAL-KILLER-CELLS; CLASS-II EXPRESSION; MEMBRANE-PROTEIN; GENE-EXPRESSION; DENDRITIC CELLS; NLRP3; INFLAMMASOME; BHRF1; PROTEIN; T-BET; EBV;

D O I：

10.3389/fimmu.2024.1297994

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The Epstein-Barr virus (EBV) is a ubiquitous human pathogen linked to various diseases, including infectious mononucleosis and multiple types of cancer. To control and eliminate EBV, the host's immune system deploys its most potent defenses, including pattern recognition receptors, Natural Killer cells, CD8+ and CD4+ T cells, among others. The interaction between EBV and the human immune system is complex and multifaceted. EBV employs a variety of strategies to evade detection and elimination by both the innate and adaptive immune systems. This demonstrates EBV's mastery of navigating the complexities of the immunological landscape. Further investigation into these complex mechanisms is imperative to advance the development of enhanced therapeutic approaches with heightened efficacy. This review provides a comprehensive overview of various mechanisms known to date, employed by the EBV to elude the immune response, while establishing enduring latent infections or instigate its lytic replication.

引用

页数：16

共 188 条

[21] Epstein Barr Virus-Associated Hodgkin Lymphoma [J].

Carbone, Antonino ;

Gloghini, Annunziata .

CANCERS, 2018, 10 (06)

[22] EBV Reactivation from Latency Is a Degrading Experience for the Host [J].

Casco, Alejandro ;

Johannsen, Eric .

VIRUSES-BASEL, 2023, 15 (03)

[23] Latent Membrane Protein 2 (LMP2) [J].

Cen, Osman ;

Longnecker, Richard .

EPSTEIN BARR VIRUS, VOL 2: ONE HERPES VIRUS: MANY DISEASES, 2015, 391 :151-180

[24] EBV-associated diseases: Current therapeutics and emerging technologies [J].

Chakravorty, Srishti ;

Afzali, Behdad ;

Kazemian, Majid .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[25] Epstein-Barr Virus BGLF4 Kinase Downregulates NF-κB Transactivation through Phosphorylation of Coactivator UXT [J].

Chang, Ling-Shih ;

Wang, Jiin-Tarng ;

Doong, Shin-Lian ;

Lee, Chung-Pei ;

Chang, Chou-Wei ;

Tsai, Ching-Hwa ;

Yeh, Sheng-Wen ;

Hsieh, Ching-Yueh ;

Chen, Mei-Ru .

JOURNAL OF VIROLOGY, 2012, 86 (22) :12176-12186

[26] MicroRNA Regulation of Human Herpesvirus Latency [J].

Chen, Siyu ;

Deng, Yue ;

Pan, Dongli .

VIRUSES-BASEL, 2022, 14 (06)

[27] Epstein-Barr virus tegument protein BGLF2 inhibits NF-κB activity by preventing p65 Ser536 phosphorylation [J].

Chen, Tao ;

Wang, Yuanfang ;

Xu, Zuo ;

Zou, Xingmei ;

Wang, Ping ;

Ou, Xiaowen ;

Li, Yiwen ;

Peng, Tao ;

Chen, Daixiong ;

Li, Meili ;

Cai, Mingsheng .

FASEB JOURNAL, 2019, 33 (09) :10563-10576

[28] Research Progress on NK Cell Receptors and Their Signaling Pathways [J].

Chen, Yingying ;

Lu, Dan ;

Churov, Alexey ;

Fu, Rong .

MEDIATORS OF INFLAMMATION, 2020, 2020

[29] Epstein-Barr Virus Glycoprotein gB and gHgL Can Mediate Fusion and Entry in trans, and Heat Can Act as a Partial Surrogate for gHgL and Trigger a Conformational Change in gB [J].

Chesnokova, Liudmila S. ;

Ahuja, Munish K. ;

Hutt-Fletcher, Lindsey M. .

JOURNAL OF VIROLOGY, 2014, 88 (21) :12193-12201

[30] NK Cell Influence on the Outcome of Primary Epstein-Barr Virus Infection [J].

Chijioke, Obinna ;

Landtwing, Vanessa ;

Muenz, Christian .

FRONTIERS IN IMMUNOLOGY, 2016, 7

← 1 2 3 4 5 6 7 8 9 10 →